AstraZeneca Pulls Plug On Lumoxiti Due To Low Uptake
Executive Summary
Signs of trouble were already emerging in 2020 when Innate backed out of a co-commercialization pact. AstraZeneca plans to discontinue the hairy cell leukemia ADC in July.
You may also be interested in...
Chastened Innate Returns Lumoxiti Rights To AZ
The French firm gave back the rights to Lumoxiti on the same day the drug got a thumbs up from the CHMP after struggling to market the rare leukemia drug in the US.
Innate Pursues Anti-Leukemic In EU
Innate Pharma pursues refractory hairy cell leukemia opportunity with first-in-class CD22-directed immunotoxin, moxetumomab pasudotox-tdfk.
Innate Pharma's Expanded IO AstraZeneca Deal Jump-Starts US Ambitions
France's Innate Pharma gets a boost to its plans to become a fully integrated biotech by forging a long-term immuno-oncology development partnership with AstraZeneca, and the setting up of a commercialization team in the US.